Figure 5. Two example RMS curves for treatment-free intervals under one of two drug regimens after first relapse of advanced ovarian cancer within 6-12 months of adjuvant therapy.

The shaded regions reflect the expected survival of the top/bottom 20% of patients showing the clinical value of the marker. It is easy to read the added value of the topotecan regimen.